Use of WS635 in medicine

WS635, a cyclosporin A derivative, addresses the lack of effective oral wound healing treatments by promoting angiogenesis and wound closure, achieving comparable healing effects to existing growth factors.

JP2024541690AActive Publication Date: 2024-11-08WATERSTONE PHARMA (WUHAN) CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2024533326
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2021-12-09
Publication Date
2024-11-08
Estimated Expiration
2041-12-09

AI Technical Summary

Technical Problem

Current wound healing treatments lack effective oral medications that directly promote wound healing, despite the potential benefits of oral formulations for ease of use and reduced healing time.

Method used

The compound WS635, a non-immunosuppressive derivative of cyclosporin A, is administered orally to promote wound healing by enhancing blood vessel generation and angiogenesis, with a daily dosage ranging from 30 mg to 1000 mg, and can be combined with other agents for accelerated healing.

Benefits of technology

WS635 significantly promotes wound healing by increasing vascularization and reducing wound area, demonstrating comparable efficacy to recombinant bovine basic fibroblast growth factor in animal models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541690000001_ABST
    Figure 2024541690000001_ABST
Patent Text Reader

Abstract

The present invention relates to a method of inducing or accelerating the wound healing process in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically effective amount of a compound of formula (I) or a stereoisomer, tautomer, N-oxide, solvate, metabolite, pharma-ceutically acceptable salt, or prodrug thereof. [Case 1] JPEG2024541690000006.jpg83122
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention belongs to the medical field. Specifically, the present invention relates to the use of (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-27-((2-(dimethylamino)ethyl)thio)-30-ethyl-33-((1R,2R,E)-1-hydroxy-2-methylhexyl-4-en-1-yl)-24-(2-hydroxy-2-methylpropyl)-6,9,1 in the manufacture of a drug for promoting the wound healing process of a patient. The present invention relates to the use of 8-triisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecanone (I) (also called WS635, SCY-635) and pharmaceutical compositions thereof. [Background technology]

[0002] The skin forms an important physical barrier to prevent microbial invasion and maintain temperature and fluid balance. Skin trauma can temporarily disrupt this barrier, posing a major health challenge. Wound healing is a complex process characterized by dynamic changes in the wound microenvironment, recruiting and guiding different types of participating cells. The overall process is typically divided into four successively overlapping phases: hemostasis, inflammation, proliferation and remodeling. In the hemostasis phase, bleeding is controlled by sympathetic nerve-induced vasoconstriction and thrombus formation. Cells of the damaged tissue release alarm signals, chemokines and growth factors, which recruit immune cells from the blood circulation and stimulate the proliferation of resident cells in the tissue, resulting in the accumulation of immune cells at the wound site. The proliferation phase is characterized by the formation of granulation tissue, which consists of neovessels, immune cells and fibroblasts, and can migrate epidermal cells into the tissue during wound re-epithelialization. During scar tissue formation, dermal and epidermal fibroblasts deposit new extracellular matrix to strengthen the repaired tissue. Different species have different skin structures and compositions, and therefore different healing rates.

[0003] Currently, most treatments for wound healing are topical and include functional dressings (e.g., interactive dressings and bioactive dressings), biomaterials (e.g., xenogeneic decellularized dermal matrix and tissue engineered skin), and negative pressure therapy techniques. Most of the traditional oral medications target the ancillary aspects of wound care, such as pain management, infection relief, and nutrition, and there is a significant lack of oral medications that directly promote wound healing. Increasing the number of oral formulations that effectively heal wounds would be of great benefit to the field of wound care, as oral formulations are easy to use and can shorten healing times.

[0004] According to the study, the open wound area of ​​the skin of the rats injected with growth factors was reduced compared to the control group. Microscopic observation showed that the levels of vascular endothelial growth factor, fibroblast growth factor and insulin growth factor were increased in the wounds injected with growth factors, promoting epithelial cell growth and angiogenesis, accelerating fibrosis and the deposition of type I collagen, and thus accelerating wound healing.

[0005] In another study, the results of ex vivo vascular remodeling evaluation of the aortas of WT and CypD KO mice showed that CypD KO mice had a faster onset and a significantly faster rate of wound closure, which was associated with increased vascularity around the wound 14 days after ear resection.

[0006] WS635 (compound represented by formula (I)) is a non-immunosuppressant derivative of cyclosporine A (CsA) with double substitution at the 3,4-position, which binds to procyclin D (CypD) and inhibits mPTP opening. Therefore, as a new type of mPTP inhibitor, WS635 is worthy of further study. Summary of the Invention [Problem to be solved by the invention]

[0007] Hereinafter, only some aspects of the present invention are summarized, and the present invention is not limited to these aspects. These aspects and other parts will be described more fully later. All references in this specification are fully incorporated herein by reference. If there is a difference between the disclosure of this specification and the cited reference, the disclosure of this specification shall be the basis.

[0008] During the research and development, the inventor unexpectedly found that WS635 can significantly promote angiogenesis in rats. Further research by the inventor has shown that WS635 can be used to promote the wound healing process. As an active ingredient in a wound healing therapeutic agent, WS635 has a small toxic effect, and in a toxicity test in which oral administration was repeated for 9 days in rats, the no obvious adverse effect level (NOAEL) dose was 80mg / kg / day. In addition, WS635 has better stability, pharmacokinetics, etc., and WS635 has been proven to be more effective in wound healing. [Means for solving the problem]

[0009] Specifically, in one aspect, the present invention relates to a method of promoting the wound healing process in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula I, or a stereoisomer, tautomer, N-oxide, solvate, metabolite, pharma- ceutically acceptable salt, or prodrug thereof. [ka]

[0010] During the course of research and development, the inventors unexpectedly discovered that WS635 can significantly promote angiogenesis in rats. According to an embodiment of the present invention, the compound represented by formula I can promote angiogenesis and promote wound healing.

[0011] In one embodiment, the wound is a surgical wound.

[0012] In one embodiment, the wound is a skin wound.

[0013] In one embodiment, the compound is administered to the subject after wounding.

[0014] In one embodiment, the compound is administered to the subject within 14 days after wounding.

[0015] In one embodiment, the compound is administered to the subject within 7 days after wounding.

[0016] In one embodiment, the compound is administered in a daily dosage of less than about 1000 mg.

[0017] In one embodiment, the compound is administered in a daily dosage of between about 30 mg and about 1000 mg.

[0018] In one embodiment, the compound is administered in a daily dosage of between about 500 mg and about 700 mg.

[0019] In one embodiment, the compound is administered once daily.

[0020] In one embodiment, the compound is administered in a single dosage once daily.

[0021] In one embodiment, the compound is administered orally.

[0022] In one embodiment, the compound is administered as a tablet, capsule or injection.

[0023] In one embodiment, the compound is administered in combination with one or more other agents, different from the compound of formula I, for inducing or accelerating the wound healing process.

[0024] In another aspect, the present invention provides the use of a compound of formula I, or a stereoisomer, tautomer, N-oxide, solvate, metabolite, pharma- ceutically acceptable salt, or prodrug thereof, in promoting the wound healing process in a subject in need thereof. [ka]

[0025] In one embodiment, the wound is a surgical wound.

[0026] In one embodiment, the wound is a skin wound.

[0027] In one embodiment, the compound is administered to the subject after wounding.

[0028] In one embodiment, the compound is administered to the subject within 14 days after wounding.

[0029] In one embodiment, the compound is administered to the subject within 7 days after wounding.

[0030] In one embodiment, the compound is administered in a daily dosage of less than about 1000 mg.

[0031] In one embodiment, the compound is administered in a daily dosage of between about 30 mg and about 1000 mg.

[0032] In one embodiment, the compound is administered in a daily dosage of between about 500 mg and about 700 mg.

[0033] In one embodiment, the compound is administered once daily.

[0034] In one embodiment, the compound is administered in a single dosage once daily.

[0035] In one embodiment, the compound is administered orally.

[0036] In one embodiment, the compound is administered as a tablet, capsule or injection.

[0037] In one embodiment, the compound is administered in combination with one or more other agents, different from the compound of formula I, for inducing or accelerating the wound healing process.

[0038] Any embodiment disclosed herein can be combined with any other embodiment, even if the embodiments are described in different aspects of the present invention, as long as these embodiments are not inconsistent with each other. Furthermore, any technical feature in one embodiment can be applied to the corresponding technical feature in other embodiments, even if the embodiments are described in different aspects of the present invention, as long as these embodiments are not inconsistent with each other.

[0039] The foregoing summarizes only some aspects disclosed herein, and is not meant to be limiting in nature. These and other aspects and embodiments are described more fully below. [Brief description of the drawings]

[0040] [Figure 1] We show that WS635 significantly promotes wound healing and its effect is comparable to that of rb-bFGF. [Diagram 2] WS635 enhances wound healing rate in a time-dependent manner. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0041] Definitions and General Terms

[0042] Some embodiments of the present invention are described in detail below, examples of which are shown in the accompanying structures and formulas. The present invention is intended to cover all alternatives, modifications and equivalents that may fall within the scope of the present invention as defined by the claims. Those skilled in the art will recognize that many of the methods and materials similar or equivalent to those described herein can be used to practice the present invention. The present invention is not limited to the methods and materials described herein. If one or more of the cited documents, patents and similar materials are different or inconsistent with the present invention, including but not limited to defined terms, use of terms, techniques described, etc., the present invention shall be the basis.

[0043] Although, for purposes of clarity, some of the features of the invention are described in the context of separate embodiments, it is to be understood that these features may also be provided in combination in a single embodiment. Rather, various features of the invention that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

[0044] Unless otherwise defined, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention pertains. All patents and publications mentioned herein are incorporated by reference in their entirety.

[0045] As used herein, the grammatical articles "a," "an," "the," and "said" are intended to include "at least one" or "one or more," unless otherwise explained herein or clearly contradicted by context. Thus, the articles used herein refer to one or to more than one (i.e., to at least one) of the grammatical objects of the article. For example, "an embodiment" refers to one or more embodiments.

[0046] The term "comprising" is an open term and means to include what is disclosed herein but not to exclude other content.

[0047] As used herein, the term "pharmacologically acceptable" means a compound, material, composition and / or dosage form that is suitable, within the scope of reasonable medical judgment, to be in contact with the tissues of a patient, free from significant toxicity, irritation, allergic response or other problem or complication, and is effective for the intended use, with reasonable benefit / risk.

[0048] The term "prodrug" refers to a compound that is converted to a compound of formula (I) in the body. For example, such conversion can be achieved by hydrolysis of the prodrug form in blood or by promoting conversion to the parent form by enzymes in blood or tissues. Prodrugs of the compounds disclosed herein can be, for example, esters. Esters used as prodrugs include phenyl esters, aliphatic (C1-24) esters, acyloxymethyl esters, carbonate esters, carbamates, and amino acid esters. For example, a hydroxy-containing compound disclosed herein is acylated at that position in its prodrug form. Other prodrug forms include phosphates, such as phosphate compounds derived from hydroxyphosphorylation on the parent compound. Detailed discussion of prodrugs is provided in the following documents: T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the ACS Symposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, J. Rautio et al., Prodrugs: Design and Clinical Applications, Nature Review Drug Discovery, 2008, 7, 255-270, and SJ Hecker et al., Prodrugs of Phosphates and Phosphonates, Journal of Medicinal Chemistry, 2008, 51, 2328-2345, which are incorporated herein by reference.

[0049] A "metabolite" is a product produced by metabolism in the body of a particular compound or its salt. Metabolites of a compound can be identified using routine techniques known in the art and their activity confirmed using the tests described herein. Such products can be produced by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, etc. of the administered compound. Thus, the present invention includes metabolites of the compounds disclosed herein, including metabolites produced by contacting the compounds disclosed herein with a mammal for a sufficiently long period of time.

[0050] "Pharmaceutically acceptable salt" refers to an organic or inorganic salt of a compound disclosed herein. Pharmaceutically acceptable salts are known in the art. For example, SM Berge et al. describes pharma-ceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977,66:1-19, which is incorporated herein by reference. Some non-limiting examples of pharma-ceutically acceptable and non-toxic salts include salts of amino groups with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, perchloric acid) or organic acids (e.g., acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, malonic acid) or salts formed using other methods used in the art (e.g., ion exchange). Other pharma- ceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, hydrogensulfate, borate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucopyranate, glyceryl phosphate, gluconate, hemisulfate, heptanoate, caproate, hydrogen iodate, 2-hydrogen phosphate, and the like. Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N-butyl salts. Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N-butyl salts. Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N-butyl salts. Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N-butyl salts. Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N-butyl salts. Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N-butyl salts. + (C 1-4 The present invention also contemplates the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Such quaternization may result in water or oil-soluble or dispersible products. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Optionally, other pharma- ceutical acceptable salts include halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, C salts, etc.1-8 These include non-toxic ammonium, quaternary ammonium, and amine cations formed with counterions such as sulfonate, or arylsulfonate.

[0051] The term "solvate" refers to an association or complex of one or more solvent molecules with a compound disclosed herein. Examples of solvents that form solvates include, but are not limited to, water, isopropyl alcohol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, ethanolamine, and mixtures thereof. The term "hydrate" refers to a complex in which the solvent molecule is water.

[0052] When the solvent is water, the term "hydrate" can be used. In one embodiment, one water molecule is associated with one molecule of the compound disclosed herein, such as a hydrate. In another embodiment, one or more water molecules are associated with one molecule of the compound disclosed herein, such as a dihydrate. In another embodiment, not more than one water molecule can be associated with one molecule of the compound disclosed herein, such as a hemihydrate. However, all solvates of the present invention retain the biological effectiveness of the non-hydrate form of the compound disclosed herein.

[0053] As used herein, the term "therapeutically effective amount" or "therapeutically effective dosage" refers to an amount of a compound disclosed herein that induces a biological or medical response (e.g., decreasing or inhibiting the activity of an enzyme or protein, ameliorating symptoms, reducing derangements, slowing the progression of a disease, etc.).

[0054] Uses of the Compounds and Pharmaceutical Compositions

[0055] The compound WS635 or the pharmaceutical composition disclosed herein can effectively promote wound healing.

[0056] An "effective amount," "therapeutically effective amount," or "effective dosage" of a compound disclosed herein or a stereoisomer, tautomer, N-oxide, solvate, metabolite, pharma- ceutically acceptable salt, or prodrug, or pharma- ceutical acceptable composition thereof is an amount that effectively promotes wound healing. Complex and pharma- ceutical acceptable compositions can be effectively administered within a fairly wide dosage range. For example, the daily dosage per person is about 30 mg to about 1000 mg, and the compound or pharma- ceutical acceptable composition can be administered in a single dose or in several divided doses per day. According to the methods disclosed herein, the compounds and compositions can be administered in any amount and by any route of administration that effectively promotes wound healing. The exact amount required will vary from subject to subject, depending on the type, age, and general condition of the subject, the severity of the infection, the particular drug, its method of administration, etc.

[0057] In some embodiments, the subject is administered a compound described herein after wound formation, for example within 14 days after wound formation. The compound described herein can be administered at a daily dose of less than about 1000 mg, for example at a daily dose of between about 30 mg and about 1000 mg, or at a daily dose of between about 500 mg and about 700 mg. The compound can be administered once a day, or in a single dose once a day.

[0058] WS635 and compositions thereof can be used for the treatment of humans as well as for the veterinary treatment of animals, such as companion animals, exotic animals, and farm mammals. In other embodiments, animals disclosed herein include horses, dogs, and cats. As used herein, the compounds disclosed herein include pharmaceutically acceptable derivatives thereof.

[0059] Working Example

[0060] Materials and Methods

[0061] Eighteen 6-week-old male SD rats were randomly divided into three groups, namely, the model group, the subject group, and the positive control group, with six rats in each group. After anesthesia, surgery for skin wounds was performed, and oral administration was started 2 hours after the skin wounds were formed. All rats were kept in the same cage. The details of the operation were as follows: all animals were anesthetized with 10% hydrochloraldehyde solution (3 ml / kg) by intraperitoneal injection, depilated on the back with a pet shaving knife, a circular marker with a diameter of 2 cm was created, the skin was disinfected with alcohol, and then the full-thickness skin was excised along the marker line with surgical scissors, and the wound surface was compressed for hemostasis. The model group was orally gavaged with 10% DMSO in corn oil, the subject group was orally gavaged with WS635 (10% DMSO dissolved in corn oil) at a dose of 52.8 mg / kg, and the positive control group was topically administered 262.5 IU / cm 2 (i.e. 62.5μl / cm 2 ) topical solution of recombinant bovine basic fibroblast growth factor (rb-bFGF) is administered once daily for 7 consecutive days. Digital photographs of the wounds of each rat are taken under the same conditions. The wounds are traced with plastic transparency paper, and the wound area is scanned with Image J software after tracing the wounds with plastic paper. Based on the wound area, the wound healing rate (%) is calculated as follows: wound healing rate (%) = (area after administration - area before administration) / area before administration x 100%.

[0062] result

[0063] Compared with the model group, the wound area of ​​the WS635 group and the positive control group (rb-bFGF) was significantly smaller on both days 3 and 7 (P<0.05, P<0.01). There was no significant discrimination between WS635 and rb-bFGF (P>0.05). Within the administration cycle, the wound healing rates of the WS635 group and the rb-bFGF group improved with the increase in administration time. The results show that oral administration of WS635 can significantly promote wound healing in the SD rat wound healing model. The results are shown in Figure 1 and Figure 2.

Claims

1. A method of promoting the wound healing process in a subject in need thereof, said method comprising the step of administering to said subject a therapeutically effective amount of a compound of formula I, or a stereoisomer, tautomer, N-oxide, solvate, metabolite, pharma- ceutically acceptable salt, or prodrug thereof. 【Chemistry 1】

2. The method of claim 1 , wherein the wound is a surgical wound.

3. The method of claim 1 , wherein the wound is a skin wound.

4. The method of claim 1 , wherein the compound is administered to the subject after the wound is formed.

5. The method of claim 1 , wherein the compound is administered to the subject within 14 days after the wound is formed.

6. The method of claim 1 , wherein the compound is administered to the subject within 7 days after the wound is formed.

7. 10. The method of claim 1, wherein the compound is administered in a daily dosage of less than about 1000 mg.

8. The method of claim 1, wherein the compound is administered in a daily dosage of between about 30 mg and about 1000 mg.

9. The method of claim 1, wherein the compound is administered in a daily dosage of between about 500 mg and about 700 mg.

10. The method of claim 1 , wherein the compound is administered once daily.

11. 10. The method of claim 1, wherein the compound is administered in a single dose once daily.

12. The method of claim 1 , wherein the compound is administered orally.

13. The method of claim 1 , wherein the compound is administered in a tablet, capsule or injection.

14. 10. The method of claim 1, wherein the compound is administered in combination with one or more other agents for inducing or accelerating the wound healing process, different from the compound of formula I.

15. The use of a compound of Formula I, or a stereoisomer, tautomer, N-oxide, solvate, metabolite, pharma- ceutically acceptable salt, or prodrug thereof, in promoting the wound healing process in a subject in need thereof. 【Chemistry 2】

16. 16. The use according to claim 15, wherein the wound is a surgical wound.

17. 16. The use according to claim 15, wherein the wound is a skin wound.

18. 16. The use of claim 15, wherein the compound is administered to the subject after the wound is formed.

19. 16. The use of claim 15, wherein the compound is administered to the subject within 14 days after formation of the wound.

20. 16. The use of claim 15, wherein the compound is administered to the subject within 7 days after formation of the wound.

21. 16. The use of claim 15, wherein the compound is administered in a daily dosage of less than about 1000 mg.

22. The use of claim 15, wherein the compound is administered in a daily dosage of between about 30 mg and about 1000 mg.

23. The use of claim 15, wherein the compound is administered in a daily dosage of between about 500 mg and about 700 mg.

24. 16. The use of claim 15, wherein the compound is administered once daily.

25. 16. The use of claim 15, wherein the compound is administered in a single dose once daily.

26. The use according to claim 15, wherein the compound is administered orally.

27. 16. The use according to claim 15, wherein the compound is administered in a tablet, capsule or injection.

28. 16. The use according to claim 15, wherein the compound is administered in combination with one or more other agents different from the compound of formula I for inducing or accelerating the wound healing process.

Citation Information

Patent Citations

  • NOVEL CYCLOSPORIN DERIVATIVES, METHODS FOR THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

    JP2001507347A

  • Pharmaceutical preparations containing cyclosporin and their use

    JP2005516931A

  • Pegylated lipid nanoparticles with bioactive lipophilic compounds

    JP2018522949A

  • Methods for wound healing and scar prevention

    JP2019510820A

  • Removal of compounds from aging cells

    JP2020521734A